Forte Biosciences (FBRX) Share-based Compensation (2016 - 2026)

Forte Biosciences (FBRX) has reported Share-based Compensation for 11 consecutive years, with $3.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation rose 96.11% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $7.8 million (up 99.87% YoY), while the FY2025 annual figure was $14.4 million, up 365.27% from the prior year.
• Share-based Compensation improved to $3.2 million in Q1 2026 per FBRX's latest filing, from $1.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $3.2 million in Q1 2026 and bottomed at $158000.0 in Q1 2022.
• Historically, Share-based Compensation has averaged $1.1 million across 5 years, with a median of $860000.0 in 2022.
• Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 68.08% — and 2023, when it surged 455.06%.
• Forte Biosciences' Share-based Compensation stood at $860000.0 in 2022, then retreated by 9.3% to $780000.0 in 2023, then slipped by 10.64% to $697000.0 in 2024, then soared by 138.74% to $1.7 million in 2025, then jumped by 90.93% to $3.2 million in 2026.
• Business Quant data shows FBRX's Share-based Compensation at $3.2 million in Q1 2026, $1.7 million in Q4 2025, and $1.5 million in Q3 2025.